Unnati Pharmax

SUTENAMO 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUTENAMO 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENAMO Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENAMO 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENAMO 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUTENAMO capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENAMO 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANAMO 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANAMO 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANAMO Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORANAMO 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORANAMO tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANAMO 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTENT 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUTENT 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENT 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENT 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUTENT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENT 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

MITANT 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

MITANT 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, MITANT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, MITANT 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. MITANT 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, MITANT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

MITANT 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

MITANT 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

MITANT 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, MITANT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, MITANT 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. MITANT 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, MITANT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

MITANT 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

Suninat 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

Suninat 50 is a high-quality Sunitinib Malate 50mg Capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, Suninat Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in solid tumors driven by angiogenesis and receptor tyrosine kinase signaling.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key receptors involved in tumor growth and angiogenesis, including VEGFR, PDGFR, KIT, and FLT3. By inhibiting these signaling pathways, Suninat 50mg Capsules effectively suppress tumor proliferation and blood vessel formation. Suninat 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib malate 50mg capsules, Suninat 50 capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, targeted oncology treatment, anti-angiogenic cancer therapy, oncology oral capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

Suninat 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTINAT 12.5 Capsules
Composition: Sunitinib Capsules 12.5mg
International Trade Name: Sutent®

SUTINAT 12.5 is a high-quality Sunitinib 12.5mg capsule, a targeted anticancer therapy internationally recognized under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTINAT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs.

Sunitinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting receptors such as VEGFR, PDGFR, KIT, and FLT3. SUTINAT 12.5 Capsules are primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUTINAT capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, targeted cancer treatment, oncology oral capsules, anticancer drug manufacturer India, pharmaceutical exporter India.

SUTINAT 12.5 Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITCAP 25mg Capsules
Composition: Sunitinib Malate Capsules 25mg
International Trade Name: Sutent®

SUNITCAP 25 is a high-quality Sunitinib Malate 25mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 25mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 25mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 25mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 25 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUTEKAST 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

Sutekast 50 mg (Sunitinib Malate Capsules) is an oral targeted anti-cancer medication used in the treatment of renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET). It contains Sunitinib Malate 50 mg, a multi-targeted tyrosine kinase inhibitor that works by blocking receptors such as VEGFR and PDGFR, thereby inhibiting tumor growth and reducing blood supply to cancer cells.

Sunitinib is globally recognized under the well-known international brand name Sutent® (by Pfizer) and is widely prescribed across the USA, Europe, and other international markets. Sutekast 50 mg is a high-quality generic alternative that offers the same therapeutic effectiveness at a more affordable cost.

This medication plays a crucial role in slowing cancer progression, reducing tumor size, and improving progression-free survival in patients with advanced or metastatic cancers. It is often used as a first-line or second-line therapy depending on the condition.

Key Benefits:

• Targets multiple cancer growth pathways

• Reduces tumor blood supply (anti-angiogenic effect)

• Helps slow disease progression and spread

• Proven global therapy with strong clinical results

Usage Instructions:
Take Sutekast 50 mg exactly as prescribed by your healthcare provider, usually once daily in cycles (commonly 4 weeks on treatment followed by 2 weeks off). It can be taken with or without food.

Safety Information:
Use under strict medical supervision. Regular monitoring of blood pressure, liver function, thyroid function, and blood counts is recommended during treatment.

International Brand Names of Sunitinib:
Sutent®, Sunitinib Teva, Sutinat, and other branded generics available worldwide.

SUNITCAP 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

SUNITCAP 50 is a high-quality Sunitinib Malate 50mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 50mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 50mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITCAP 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

SUNITCAP 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITCAP Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib Malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITCAP 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITCAP 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUNITCAP capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITCAP 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAT 10 Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENVAT 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAT 10mg Tablets effectively reduce tumor proliferation and vascularization. LENVAT 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENVAT tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAT 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAT 4 Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVAT 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVAT Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVAT 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVAT 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVAT capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVAT 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENSHIL 10mg Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

LENSHIL 10 is a high-quality Lenvatinib 10mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENSHIL Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENSHIL 10mg Tablets effectively reduce tumor proliferation and vascularization. LENSHIL 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg tablets, LENSHIL tablets, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENSHIL 10 Lenvatinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVA 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVA 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVA 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVA 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVA capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVA 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENTRIS 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENTRIS 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENTRIS Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENTRIS 4mg Capsules effectively reduce tumor proliferation and vascularization. LENTRIS 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENTRIS capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENTRIS 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAKAST 10mg Tablets
Composition: Lenvatinib Tablets 10mg
International Trade Name: Lenvima®

Lenvakast 10 mg (Lenvatinib Tablets) is a targeted oral anti-cancer medication used in the treatment of thyroid cancer, hepatocellular carcinoma (liver cancer), and advanced renal cell carcinoma (kidney cancer). It contains Lenvatinib 10 mg, a potent tyrosine kinase inhibitor that works by blocking multiple receptors such as VEGFR, FGFR, and PDGFR, thereby inhibiting tumor growth and reducing the blood supply to cancer cells.

Lenvatinib is globally recognized under the well-known international brand name Lenvima® (by Eisai) and is widely prescribed across the USA, Europe, and other global markets. Lenvakast 10 mg is a high-quality generic alternative that provides the same therapeutic effectiveness at a more affordable price.

This medication plays a crucial role in slowing cancer progression, reducing tumor size, and improving progression-free survival in patients with advanced or metastatic cancers. It may be used alone or in combination with other treatments depending on the patient’s condition.

Key Benefits:

• Targets multiple cancer growth pathways

• Reduces tumor blood supply (anti-angiogenic effect)

• Helps slow disease progression and spread

• Globally trusted molecule with proven results

Usage Instructions:
Take Lenvakast 10 mg exactly as prescribed by your healthcare provider, with or without food. Swallow the tablet whole with water.

Safety Information:
Use under strict medical supervision. Regular monitoring of blood pressure, liver function, kidney function, and overall health is essential during treatment.

 

International Brand Names of Lenvatinib:
Lenvima®, Lenvanix, Lenvat, and other branded generics available worldwide.

LENSHIL 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENSHIL 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENSHIL Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENSHIL 4mg Capsules effectively reduce tumor proliferation and vascularization. LENSHIL 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENSHIL capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENSHIL 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVABUZZ 4mg Capsules
Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

LENVABUZZ 4 is a high-quality Lenvatinib 4mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVABUZZ Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVABUZZ 4mg Capsules effectively reduce tumor proliferation and vascularization. LENVABUZZ 4mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 4mg capsules, LENVABUZZ capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVABUZZ 4 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVALIEVA 10mg Capsules
Composition: Lenvatinib Capsules 10mg
International Trade Name: Lenvima®

LENVALIEVA 10 is a high-quality Lenvatinib 10mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Lenvima®. Manufactured in WHO-GMP certified facilities, LENVALIEVA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Lenvatinib is a multi-targeted tyrosine kinase inhibitor (TKI) that blocks key signaling pathways involved in tumor growth and angiogenesis by inhibiting VEGFR, FGFR, PDGFR, KIT, and RET receptors. Through targeted pathway suppression, LENVALIEVA 10mg Capsules effectively reduce tumor proliferation and vascularization. LENVALIEVA 10mg is primarily indicated for the treatment of differentiated thyroid cancer (DTC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and endometrial carcinoma, either as monotherapy or in combination with other anticancer agents.

Lenvatinib 10mg capsules, LENVALIEVA capsules, Lenvima biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

LENVALIEVA 10 Lenvatinib Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

LENVAKAST 4mg Capsules

Composition: Lenvatinib Capsules 4mg
International Trade Name: Lenvima®

Lenvakast 4 mg (Lenvatinib Tablets) is a targeted oral anti-cancer medication used in the treatment of thyroid cancer, hepatocellular carcinoma (liver cancer), and advanced renal cell carcinoma (kidney cancer). It contains Lenvatinib 4 mg, a potent tyrosine kinase inhibitor that works by blocking multiple receptors (VEGFR, FGFR, PDGFR), thereby inhibiting tumor growth and reducing blood supply to cancer cells.

Lenvatinib is globally recognized under the well-known international brand name Lenvima® (by Eisai) and is widely prescribed across the USA, Europe, and other global markets. Lenvakast 4 mg is a high-quality generic alternative that provides the same therapeutic effectiveness at a more affordable price.

This medication plays an important role in slowing cancer progression, reducing tumor size, and improving progression-free survival in patients with advanced or metastatic cancers. It is often used alone or in combination with other therapies depending on the condition.

Key Benefits:

• Targets multiple pathways involved in tumor growth

• Reduces blood supply to tumors (anti-angiogenic effect)

• Helps slow cancer progression and spread

• Globally trusted molecule with proven clinical results

Usage Instructions:
Take Lenvakast 4 mg exactly as prescribed by your healthcare provider, with or without food. Swallow the tablet whole with water.

Safety Information:
Use under strict medical supervision. Regular monitoring of blood pressure, liver function, and kidney function is required during treatment.

International Brand Names of Lenvatinib:
Lenvima®, Lenvanix, Lenvat, and other branded generics available worldwide.

CABONROM 20mg Tablets
Composition: Cabozantinib Tablets 20mg
International Trade Name: Cabometyx®

CABONROM 20 is a high-quality Cabozantinib 20mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Cabometyx®. Manufactured in WHO-GMP certified facilities, CABONROM Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that inhibits key signaling pathways involved in tumor growth, metastasis, and angiogenesis by targeting MET, VEGFR, AXL, RET, and other receptor kinases. Through targeted pathway suppression, CABONROM 20mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CABONROM 20mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC).

Cabozantinib 20mg tablets, CABONROM tablets, Cabometyx biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CABONROM 20 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CAZANAT 60mg Tablets
Composition: Cabozantinib Tablets 60mg
International Trade Name: Cabometyx®, Cometriq®

CAZANAT 60 is a high-quality Cabozantinib 60mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand names Cabometyx® and Cometriq®. Manufactured in WHO-GMP certified facilities, CAZANAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CAZANAT 60mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CAZANAT 60mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC).

Cabozantinib 60mg tablets, CAZANAT tablets, Cabometyx® biosimilar, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CAZANAT 60 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CAZANAT 20mg Tablets
Composition: Cabozantinib Tablets 20mg
International Trade Name: Cabometyx®, Cometriq®

CAZANAT 20 is a high-quality Cabozantinib 20mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand names Cabometyx® and Cometriq®. Manufactured in WHO-GMP certified facilities, CAZANAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CAZANAT 20mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CAZANAT 20mg is primarily indicated for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and medullary thyroid carcinoma (MTC).

Cabozantinib 20mg tablets, CAZANAT tablets, Cabometyx® biosimilar, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CAZANAT 20 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CABOTRES 40mg Tablets
Composition: Cabozantinib Tablets 40mg
International Trade Name: Cometriq®

CABOTRES 40 is a high-quality Cabozantinib 40mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Cometriq®. Manufactured in WHO-GMP certified facilities, CABOTRES Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in receptor tyrosine kinase–dependent malignancies.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth, metastasis, and angiogenesis by inhibiting key receptors including MET, VEGFR, AXL, and RET. CABOTRES 40mg Tablets effectively reduce tumor proliferation, invasion, and tumor vascularization. CABOTRES 40mg is primarily indicated for the treatment of medullary thyroid carcinoma (MTC), advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC).

Cabozantinib 40mg tablets, CABOTRES tablets, Cometriq® biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

CABOTRES 40 Cabozantinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANIB 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANIB 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANIB Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in kinase-driven and angiogenesis-dependent malignancies.

Sorafenib is a multi-kinase inhibitor that targets tumor cell proliferation and angiogenesis by inhibiting key receptors including VEGFR, PDGFR, RAF kinases, and c-KIT. By suppressing these signaling pathways, SORANIB 200mg Tablets effectively reduce tumor growth and vascularization. SORANIB 200mg is primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORANIB tablets, Nexavar biosimilar, kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANIB 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORALIEVA 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORALIEVA 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORALIEVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORALIEVA 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORALIEVA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORALIEVA 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORAFEKAST 200mg Tablets

Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

Sorafekast 200 mg (Sorafenib Tablets) is an oral targeted anti-cancer medication used in the treatment of hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), and differentiated thyroid cancer. It contains Sorafenib 200 mg, a multikinase inhibitor that works by blocking tumor cell proliferation and reducing blood supply to cancer cells, thereby slowing tumor growth and progression.

Sorafenib is globally recognized under the well-known international brand name Nexavar® (by Bayer) and is widely prescribed across the USA, Europe, and other international markets. Sorafekast 200 mg is a high-quality generic alternative that offers the same therapeutic effectiveness at a more affordable price.

This medication plays a key role in controlling advanced cancers, reducing tumor spread, and improving progression-free survival in patients. It is commonly used when surgery or other treatments are not suitable.

Key Benefits:

• Inhibits multiple cancer growth pathways

• Reduces tumor blood supply (anti-angiogenic effect)

• Helps slow disease progression

• Globally trusted molecule with proven clinical results

Usage Instructions:
Take Sorafekast 200 mg exactly as prescribed by your healthcare provider, usually on an empty stomach (at least 1 hour before or 2 hours after food).

Safety Information:
Use under strict medical supervision. Regular monitoring of liver function, blood pressure, and skin reactions is recommended during treatment.

 

International Brand Names of Sorafenib:
Nexavar®, Sorafenat, Soranib, and other branded generics available worldwide.

SORAFIKAST 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORAFIKAST 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORAFIKAST Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORAFIKAST 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORAFIKAST tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORAFIKAST 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORANAMA Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORANAMA is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORANAMA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORANAMA Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib tablets, SORANAMA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORANAMA Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SORALIEVA 200mg Tablets
Composition: Sorafenib Tablets 200mg
International Trade Name: Nexavar®

SORALIEVA 200 is a high-quality Sorafenib 200mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Nexavar®. Manufactured in WHO-GMP certified facilities, SORALIEVA Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in multi-kinase inhibitor therapy for solid tumors.

Sorafenib is a multi-kinase inhibitor that targets RAF kinase, VEGFR, PDGFR, and other key signaling pathways involved in tumor growth, angiogenesis, and metastasis. SORALIEVA 200mg Tablets are primarily indicated for the treatment of advanced hepatocellular carcinoma (HCC), differentiated thyroid carcinoma (DTC), and renal cell carcinoma (RCC).

Sorafenib 200mg tablets, SORALIEVA tablets, Nexavar® biosimilar, multi-kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

SORALIEVA 200 Sorafenib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

GEFTINAT 250 Tablets
Composition: Gefitinib Tablets IP 250mg
International Trade Name: Iressa®

GEFTINAT 250 is a high-quality Gefitinib 250mg tablet, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Iressa®. Manufactured in WHO-GMP certified facilities, GEFTINAT Tablets are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in EGFR mutation–positive non-small cell lung cancer (NSCLC).

Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that blocks EGFR signaling pathways, thereby inhibiting cancer cell proliferation and survival. GEFTINAT 250mg Tablets are primarily indicated for the first-line and subsequent treatment of locally advanced or metastatic NSCLC in patients with activating EGFR mutations.

Gefitinib 250mg tablets, GEFTINAT tablets, Iressa biosimilar, EGFR tyrosine kinase inhibitor therapy, targeted oncology tablets, pharmaceutical exporter India, and anticancer drug manufacturer India.

GEFTINAT 250 Gefitinib Tablets are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The tablets are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

CABOTRES 60 MG Composition: CABOZANTINIB 60 MG International Trade Name: CABOMETYX®
Cabotres 60 Tablets is an oral anticancer medication used in the treatment of advanced cancers. It contains Cabozantinib 60 mg, a targeted therapy that works by blocking specific proteins involved in tumor growth and the formation of new blood vessels that feed cancer cells. Manufactured by BDR Pharmaceuticals, Cabotres 60 Tablets are developed under strict quality standards to support effective and reliable oncology treatment.
Cabozantinib belongs to a class of medicines known as tyrosine kinase inhibitors. It acts by inhibiting multiple receptor tyrosine kinases that play a key role in cancer cell growth, spread, and angiogenesis. By disrupting these signaling pathways, Cabotres helps slow tumor progression and may reduce the spread of cancer to other parts of the body. This targeted mechanism makes it an important option in modern cancer therapy.
Cabotres 60 Tablets are commonly prescribed for the treatment of advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and certain types of thyroid cancer, as recommended by an oncologist. The tablet is taken orally once daily on an empty stomach, usually at least one hour before or two hours after meals. It should be swallowed whole with water and not crushed or chewed. The dosage and duration of treatment depend on the patient’s medical condition and response to therapy.
Patients taking Cabotres require regular medical monitoring, including blood tests and clinical evaluations, to assess treatment effectiveness and detect side effects early. Common side effects may include fatigue, diarrhea, nausea, decreased appetite, high blood pressure, mouth sores, and weight loss. Because the medication can affect normal cells as well as cancer cells, some patients may experience more serious reactions. Symptoms such as severe abdominal pain, unusual bleeding, or persistent high blood pressure should be reported to a healthcare provider immediately.
Important safety precautions must be followed during treatment. Cabotres is not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant. Effective contraception is advised during therapy and for a period after the last dose. Patients with a history of heart disease, liver problems, or bleeding disorders should inform their doctor before starting treatment. Alcohol and grapefruit products should generally be avoided, as they may interfere with how the medicine works.
Cabotres 60 Tablets are supplied in secure packaging to maintain stability and potency and should be stored in a cool, dry place away from direct sunlight. The product is manufactured in compliance with recognized pharmaceutical standards, ensuring consistent quality for clinical use. As part of a comprehensive cancer care plan, Cabotres is often combined with supportive therapies and close follow-up by oncology specialists.
When taken under expert medical supervision, Cabotres 60 Tablets provide an effective targeted treatment option for certain advanced cancers. Strict adherence to the prescribed schedule and ongoing communication with healthcare professionals are essential to maximize benefits and manage risks safely.

CAPBRUSAM
Composition: Acalabrutinib Capsule
International Trade Name: Calquence ®

Capbrusam Acalabrutinib Capsule is a prescription anticancer medicine that contains acalabrutinib as its active ingredient. It is primarily used in the treatment of certain types of blood cancers, particularly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Acalabrutinib belongs to a class of medicines known as Bruton’s tyrosine kinase (BTK) inhibitors, which are targeted therapies designed to block specific proteins involved in cancer cell growth and survival.
Acalabrutinib works by selectively inhibiting the Bruton’s tyrosine kinase enzyme, a key component in the B-cell receptor signaling pathway. This pathway plays an important role in the growth, activation, and survival of malignant B-cells. By blocking BTK activity, acalabrutinib interferes with signals that help cancer cells multiply and resist programmed cell death. As a result, the medicine slows down the progression of the disease and may reduce the number of abnormal cancer cells in the blood and lymph nodes.
Capbrusam Acalabrutinib Capsule is taken orally and is usually prescribed to be taken twice daily, approximately 12 hours apart. The capsules should be swallowed whole with water and should not be opened, broken, or chewed. It can generally be taken with or without food. Patients should follow their doctor’s instructions carefully regarding dosing schedules, as consistent timing is important to maintain effective drug levels in the body.
This medicine is commonly used in patients who are newly diagnosed with chronic lymphocytic leukemia or those whose disease has relapsed or become resistant to previous treatments. It may be used alone or in combination with other therapies, depending on the specific clinical situation. Targeted therapies like acalabrutinib have significantly improved outcomes in B-cell malignancies by offering more precise action compared to traditional chemotherapy, often with a more favorable side effect profile.
Like all anticancer medications, Capbrusam Acalabrutinib Capsule may cause side effects. Common side effects include headache, diarrhea, muscle pain, joint pain, upper respiratory tract infections, fatigue, and bruising. Some patients may experience low blood counts, which can increase the risk of infection, anemia, or bleeding. More serious but less common side effects include severe infections, irregular heartbeat (such as atrial fibrillation), bleeding problems, and the potential development of secondary cancers. Patients should immediately report symptoms such as unusual bleeding, persistent fever, chest pain, or irregular heartbeat.
Because acalabrutinib can affect platelet function and increase bleeding risk, caution is required in patients taking blood thinners or undergoing surgery. Doctors may advise temporarily stopping the medication before certain medical or dental procedures. Regular blood tests and clinical monitoring are necessary throughout treatment to assess response and detect any complications early.
Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, as some medicines can interact with acalabrutinib. Drugs that strongly affect liver enzymes, particularly CYP3A inhibitors or inducers, may alter the effectiveness of the treatment. Antacids and acid-reducing agents may also interfere with absorption and should be used with appropriate timing adjustments as directed by a physician.
Pregnancy and breastfeeding should be avoided during treatment with acalabrutinib, as its safety in pregnant women is not well established and it may pose risks to the fetus. Women of childbearing potential should use effective contraception during treatment and for a recommended period after the last dose. 

Sutinat Sunitinib Malate Capsule 50 mg

Sutinat Sunitinib Malate Capsule 50 mg is a targeted anticancer medication used to treat certain types of cancers by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs) that block proteins responsible for tumor growth and blood supply to cancer cells.

This medicine is commonly prescribed for patients with kidney cancer, gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors. By blocking specific signals that allow cancer cells to grow and spread, Sutinat helps control disease progression and improve treatment outcomes.

Manufactured with high-quality pharmaceutical standards, Sutinat 50 mg capsules provide an effective option for oncologists and patients seeking targeted cancer therapy.

Key Benefits of Sutinat 50 mg

• Helps slow the growth and spread of cancer cells

• Used in the treatment of renal cell carcinoma (kidney cancer)

• Effective for gastrointestinal stromal tumors (GIST)

• Also prescribed for pancreatic neuroendocrine tumors

• Works as a targeted therapy that blocks tumor blood supply

• Helps improve disease control and treatment response

Uses of Sutinat Sunitinib Malate Capsule

Doctors commonly prescribe Sutinat 50 mg for the treatment of:

• Advanced Kidney Cancer (Renal Cell Carcinoma)

• Gastrointestinal Stromal Tumor (GIST) when other treatments fail

• Pancreatic Neuroendocrine Tumors (pNET)

How Sutinat 50 mg Works

Sunitinib works by inhibiting multiple tyrosine kinase receptors, which are responsible for tumor growth and the formation of blood vessels that feed cancer cells. By blocking these pathways, the medicine helps reduce tumor growth and prevent cancer progression.

Dosage and Administration

• Take Sutinat Sunitinib 50 mg exactly as prescribed by your doctor.

• Usually taken once daily, with or without food.

• Swallow the capsule whole with water.

• Do not crush, chew, or break the capsule.

• The dosage and treatment cycle may vary depending on the patient’s medical condition.

Always follow your oncologist’s instructions for safe and effective treatment.

Possible Side Effects

Some patients may experience side effects, including:

• Fatigue

• Nausea or vomiting

• High blood pressure

• Diarrhea

• Mouth sores

• Skin discoloration

• Loss of appetite

If any severe side effects occur, consult your doctor immediately.

Precautions and Warnings

• Use this medicine only under medical supervision.

• Inform your doctor about any heart, liver, or kidney conditions.

• Not recommended during pregnancy or breastfeeding.

• Regular blood tests and monitoring may be required during treatment.

Frequently Asked Questions (FAQ)

1. What is Sutinat 50 mg used for?
Sutinat 50 mg is used to treat kidney cancer, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors.

2. How long does Sunitinib treatment last?
Treatment duration depends on the patient’s response and doctor’s recommendation.

3. Can Sutinat cure cancer?
Sutinat helps control and slow cancer growth but is usually part of a long-term treatment plan.

4. Is Sutinat 50 mg chemotherapy?
No, it is a targeted therapy drug, which works differently from traditional chemotherapy.

Cabozer 40 mg (Cabozantinib Tablets) is an oral targeted anti-cancer medication used in the treatment of various advanced cancers, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and differentiated thyroid cancer. It contains Cabozantinib 40 mg, a tyrosine kinase inhibitor that works by blocking specific proteins (VEGFR, MET, and AXL) responsible for tumor growth, angiogenesis, and cancer progression.

Cabozantinib is internationally recognized and marketed under popular global brand names such as Cabometyx® (by Exelixis) and Cometriq®, widely used across countries including the USA, Europe, and other international markets. Cabozer is a high-quality generic version that offers the same therapeutic benefits at a more affordable price.

This medication helps slow down cancer growth, reduce tumor spread, and improve progression-free survival in patients with advanced or metastatic cancers. It is commonly prescribed when other treatments are no longer effective or as part of combination therapy depending on the condition.

Key Benefits:

• Targets multiple cancer growth pathways

• Helps slow tumor progression and spread

• Improves survival outcomes in advanced cancers

• Trusted globally with proven clinical effectiveness

Usage Instructions:
Take Cabozer 40 mg exactly as prescribed by your doctor, usually once daily on an empty stomach. Avoid eating at least 2 hours before and 1 hour after taking the tablet.

Safety Information:
Use under strict medical supervision. Regular monitoring of liver function, blood pressure, and overall health is recommended during treatment. Do not self-medicate.

International Brand Names of Cabozantinib:
Cabometyx®, Cometriq®, Cabozanix, Caboxen, and other branded generics available worldwide.

Cabozer 60 mg (Cabozantinib Tablets) is an advanced oral targeted therapy used in the treatment of multiple cancers, including renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and differentiated thyroid cancer. It contains Cabozantinib 60 mg, a potent tyrosine kinase inhibitor that blocks key proteins such as VEGFR, MET, and AXL, which are responsible for tumor growth, angiogenesis, and cancer spread.

Cabozantinib is globally recognized under well-known international brand names such as Cabometyx® (by Exelixis) and Cometriq®, and is widely prescribed across the USA, Europe, and other international markets. Cabozer 60 mg is a high-quality generic alternative that delivers the same therapeutic effectiveness at a more affordable cost.

This medication plays a crucial role in slowing cancer progression, reducing tumor size, and improving progression-free survival in patients with advanced or metastatic cancers. It is often recommended when other treatments are ineffective or as part of combination therapy based on the patient’s condition.

Key Benefits:

• Targets multiple cancer growth pathways

• Helps slow tumor progression and metastasis

• Improves survival outcomes in advanced cancers

• Globally trusted molecule with proven results

Usage Instructions:
Take Cabozer 60 mg exactly as prescribed by your healthcare provider, usually once daily on an empty stomach. Avoid food at least 2 hours before and 1 hour after taking the tablet.

Safety Information:
Use only under medical supervision. Regular monitoring of liver function, blood pressure, and other health parameters is essential during treatment.

International Brand Names of Cabozantinib:
Cabometyx®, Cometriq®, Cabozanix, Caboxen, and other branded generics available worldwide.

Sutekast 25 mg (Sunitinib Malate Capsules/Tablets) is an oral targeted anti-cancer medication used in the treatment of renal cell carcinoma (kidney cancer), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (pNET). It contains Sunitinib Malate 25 mg, a multi-targeted tyrosine kinase inhibitor that works by blocking receptors such as VEGFR and PDGFR, thereby inhibiting tumor growth and reducing blood supply to cancer cells.

Sunitinib is globally recognized under the well-known international brand name Sutent® (by Pfizer) and is widely prescribed across the USA, Europe, and other international markets. Sutekast 25 mg is a high-quality generic alternative that offers the same therapeutic effectiveness at a more affordable price.

This medication helps slow cancer progression, reduce tumor size, and improve progression-free survival in patients with advanced or metastatic cancers. It is commonly used as a first-line or second-line therapy depending on the patient’s condition.

Key Benefits:

• Targets multiple cancer growth pathways

• Reduces tumor blood supply (anti-angiogenic effect)

• Helps slow disease progression and spread

• Globally trusted molecule with proven clinical results

Usage Instructions:
Take Sutekast 25 mg exactly as prescribed by your healthcare provider, usually once daily in treatment cycles (commonly 4 weeks on treatment followed by 2 weeks off). It can be taken with or without food.

Safety Information:
Use under strict medical supervision. Regular monitoring of blood pressure, liver function, thyroid function, and blood counts is essential during treatment.

International Brand Names of Sunitinib:
Sutent®, Sunitinib Teva, Sutinat, and other branded generics available worldwide.

SUTENAMO 50mg Capsules
Composition: Sunitinib Malate Capsules 50mg
International Trade Name: Sutent®

SUTENAMO 50 is a high-quality Sunitinib Malate 50mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUTENAMO Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven solid tumors.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUTENAMO 50mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUTENAMO 50mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib malate 50mg capsules, SUTENAMO capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUTENAMO 50 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.

SUNITYRA 12.5mg Capsules
Composition: Sunitinib Malate Capsules 12.5mg
International Trade Name: Sutent®

SUNITYRA 12.5 is a high-quality Sunitinib Malate 12.5mg capsule, a biosimilar equivalent of the internationally recognized targeted anticancer therapy marketed under the brand name Sutent®. Manufactured in WHO-GMP certified facilities, SUNITYRA Capsules are supplied by trusted pharmaceutical exporters from India to support advanced global oncology treatment programs, particularly in angiogenesis-driven and receptor tyrosine kinase–dependent malignancies.

Sunitinib malate is a multi-targeted tyrosine kinase inhibitor (TKI) that suppresses tumor growth and angiogenesis by inhibiting key receptors such as VEGFR, PDGFR, KIT, and FLT3. Through targeted pathway inhibition, SUNITYRA 12.5mg Capsules effectively reduce cancer cell proliferation and tumor vascularization. SUNITYRA 12.5mg is primarily indicated for the treatment of metastatic renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST) after imatinib failure, and pancreatic neuroendocrine tumors (pNETs).

Sunitinib 12.5mg capsules, SUNITYRA capsules, Sutent biosimilar, tyrosine kinase inhibitor therapy, anti-angiogenic cancer treatment, targeted oncology capsules, pharmaceutical exporter India, and anticancer drug manufacturer India.

SUNITYRA 12.5 Sunitinib Malate Capsules are manufactured under stringent GMP and quality standards, ensuring consistent efficacy, safety, and long-term stability. The capsules are supplied in secure, export-grade packaging with complete regulatory documentation, making them suitable for oncology hospitals, specialty cancer clinics, government cancer programs, and international pharmaceutical distributors.